aflibercept   Click here for help

GtoPdb Ligand ID: 6786

Synonyms: AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept
Approved drug
aflibercept is an approved drug (FDA (2011), EMA (2012))
Compound class: Antibody
Comment: Alfibercept is a fusion protein combining the Fc portion of human IgG with the ligand binding domains of the VEGRF1 and VEGRF2 receptors.

Biosimilars:
Patent protection for originator alfibercept is expected to expire earliest in Japan and China (2022), then in US (2023, if Regeneron's extended patent claims are accepted) and the EU (2025), and biosimilar development is underway [3]. Examples include Momenta Pharmaceuticals/Mylan's M710, Alteogen's ALT-L9 (a heat stabilised formulation with a predicted longer shelf-life than Eylea; NCT04058535), and Formycon/Santo Holdings' FYB203.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
VEGFA Primary target of this compound Hs Antagonist Inhibition - - - 1-2,4
[1-2,4]